临床试验

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT：NCT06790784 · RECRUITING

NCT编号NCT06790784

状态RECRUITING

开始日期2025-08-04

SponsorJaeb Center for Health Research (OTHER)

First posted2025-01-24

Last updated2026-09-18

简要摘要

This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。